Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cancer Cell. 2018 May 14;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002.

PMID:
29763624
2.

Diffusing Innovation and Best Practice in Health Care.

Greilich PE, Phelps ME, Daniel W.

Anesthesiol Clin. 2018 Mar;36(1):127-141. doi: 10.1016/j.anclin.2017.10.009. Review.

PMID:
29425595
3.

Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer.

Collins J, Waldmann CM, Drake C, Slavik R, Ha NS, Sergeev M, Lazari M, Shen B, Chin FT, Moore M, Sadeghi S, Phelps ME, Murphy JM, van Dam RM.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11309-11314. doi: 10.1073/pnas.1710466114. Epub 2017 Oct 10.

4.

Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. doi: 10.1073/pnas.1706689114. Epub 2017 Sep 5.

6.

Cancer Research in the 21st Century.

Economou JS, Slamon DJ, Ribas A, Phelps ME.

Ann Surg. 2016 Oct;264(4):555-65. doi: 10.1097/SLA.0000000000001926. No abstract available.

PMID:
27537535
7.

[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4027-32. doi: 10.1073/pnas.1524212113. Epub 2016 Mar 28.

8.

Quantitative assessments of glycolysis from single cells.

Shin YS, Kim J, Johnson D, Dooraghi AA, Mai WX, Ta L, Chatziioannou AF, Phelps ME, Nathanson DA, Heath JR.

Technology (Singap World Sci). 2015 Jun;3(4):172-178. Epub 2015 Jun 25.

9.

Development of 2-Deoxy-2-[(18)F]fluororibose for Positron Emission Tomography Imaging Liver Function in Vivo.

Evdokimov NM, Clark PM, Flores G, Chai T, Faull KF, Phelps ME, Witte ON, Jung ME.

J Med Chem. 2015 Jul 23;58(14):5538-47. doi: 10.1021/acs.jmedchem.5b00569. Epub 2015 Jul 2.

10.

Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.

Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS.

J Nucl Med. 2015 Jan;56(1):70-5. doi: 10.2967/jnumed.114.148247. Epub 2014 Dec 11.

11.

Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-to-mesenchymal transition.

Zadran S, Arumugam R, Herschman H, Phelps ME, Levine RD.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13235-40. doi: 10.1073/pnas.1414714111. Epub 2014 Aug 25.

12.

Positron emission tomography probe demonstrates a striking concentration of ribose salvage in the liver.

Clark PM, Flores G, Evdokimov NM, McCracken MN, Chai T, Nair-Gill E, O'Mahony F, Beaven SW, Faull KF, Phelps ME, Jung ME, Witte ON.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2866-74. doi: 10.1073/pnas.1410326111. Epub 2014 Jun 30.

13.

INDs for PET molecular imaging probes-approach by an academic institution.

Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME.

Mol Imaging Biol. 2014 Aug;16(4):441-8. doi: 10.1007/s11307-014-0735-2.

14.

Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W.

Clin Cancer Res. 2014 Jul 1;20(13):3550-9. doi: 10.1158/1078-0432.CCR-13-1440. Epub 2014 Mar 31.

15.

¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.

Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1199-209. doi: 10.1007/s00259-013-2678-2. Epub 2014 Mar 7.

16.

Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.

Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG.

J Exp Med. 2014 Mar 10;211(3):473-86. doi: 10.1084/jem.20131738. Epub 2014 Feb 24.

17.

Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W.

Neuro Oncol. 2014 Apr;16(4):603-9. doi: 10.1093/neuonc/not166. Epub 2013 Dec 4.

18.

(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.

Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W.

J Nucl Med. 2014 Jan;55(1):30-6. doi: 10.2967/jnumed.113.121418. Epub 2013 Oct 28.

19.

Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system.

Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR.

J Nucl Med. 2013 Oct;54(10):1820-4. doi: 10.2967/jnumed.112.118497. Epub 2013 Aug 26.

20.

Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.

Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG.

J Med Chem. 2013 Sep 12;56(17):6696-708. doi: 10.1021/jm400457y. Epub 2013 Aug 15.

21.

ELIXYS - a fully automated, three-reactor high-pressure radiosynthesizer for development and routine production of diverse PET tracers.

Lazari M, Quinn KM, Claggett SB, Collins J, Shah GJ, Herman HE, Maraglia B, Phelps ME, Moore MD, van Dam RM.

EJNMMI Res. 2013 Jul 12;3(1):52. doi: 10.1186/2191-219X-3-52.

22.

Plug-and-play modules for flexible radiosynthesis.

Herman H, Flores G, Quinn K, Eddings M, Olma S, Moore MD, Ding H, Bobinski KP, Wang M, Williams D, Wiliams D, Shen CK, Phelps ME, Michael van Dam R.

Appl Radiat Isot. 2013 Aug;78:113-24. doi: 10.1016/j.apradiso.2013.04.023. Epub 2013 Apr 25.

23.

NEMA NU-4 performance evaluation of PETbox4, a high sensitivity dedicated PET preclinical tomograph.

Gu Z, Taschereau R, Vu NT, Wang H, Prout DL, Silverman RW, Bai B, Stout DB, Phelps ME, Chatziioannou AF.

Phys Med Biol. 2013 Jun 7;58(11):3791-814. doi: 10.1088/0031-9155/58/11/3791. Epub 2013 May 10.

24.

PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors.

Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF.

PET Clin. 2013 Apr;8(2):201-17. doi: 10.1016/j.cpet.2012.09.002. Epub 2012 Oct 23.

PMID:
27157948
25.

Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.

Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG.

J Exp Med. 2012 Nov 19;209(12):2215-28. doi: 10.1084/jem.20121061. Epub 2012 Nov 12.

26.

18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.

Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM.

Neuro Oncol. 2012 Aug;14(8):1079-89. doi: 10.1093/neuonc/nos141. Epub 2012 Jun 18.

27.

18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2012 Apr 1;18(7):2024-31. doi: 10.1158/1078-0432.CCR-11-2139. Epub 2012 Feb 14.

28.

Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.

Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J.

J Nucl Med. 2012 Mar;53(3):393-8. doi: 10.2967/jnumed.111.095711. Epub 2012 Feb 9.

29.

Micro-chemical synthesis of molecular probes on an electronic microfluidic device.

Keng PY, Chen S, Ding H, Sadeghi S, Shah GJ, Dooraghi A, Phelps ME, Satyamurthy N, Chatziioannou AF, Kim CJ, van Dam RM.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):690-5. doi: 10.1073/pnas.1117566109. Epub 2011 Dec 30.

30.

3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W.

J Nucl Med. 2012 Jan;53(1):29-36. doi: 10.2967/jnumed.111.092387. Epub 2011 Dec 12.

31.

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.

Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS.

J Nucl Med. 2011 Nov;52(11):1684-1689. doi: 10.2967/jnumed.111.095257.

32.

18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.

Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J.

Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.

PMID:
21936620
33.

Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.

Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC.

Clin Cancer Res. 2011 Oct 15;17(20):6553-62. doi: 10.1158/1078-0432.CCR-10-3290. Epub 2011 Aug 25.

34.

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK.

Cancer Res. 2011 Aug 1;71(15):5164-74. doi: 10.1158/0008-5472.CAN-10-4633. Epub 2011 Jun 6.

35.

Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network.

Shin J, Kepe V, Small GW, Phelps ME, Barrio JR.

Int J Alzheimers Dis. 2011;2011:687945. doi: 10.4061/2011/687945. Epub 2011 Apr 19.

36.

Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography.

Liu K, Lepin EJ, Wang MW, Guo F, Lin WY, Chen YC, Sirk SJ, Olma S, Phelps ME, Zhao XZ, Tseng HR, Michael van Dam R, Wu AM, Shen CK.

Mol Imaging. 2011 Jun;10(3):168-76, 1-7.

37.

Metabolic imaging allows early prediction of response to vandetanib.

Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA.

J Nucl Med. 2011 Feb;52(2):231-40. doi: 10.2967/jnumed.110.081745. Epub 2011 Jan 13.

38.

Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.

Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):711-21. doi: 10.1007/s00259-010-1666-z. Epub 2010 Dec 3.

39.

Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions?

Phelps ME, Barrio JR.

Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17459-60. doi: 10.1073/pnas.1012684107. Epub 2010 Oct 4. No abstract available.

40.

Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.

Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W.

J Nucl Med. 2010 Oct;51(10):1532-8. doi: 10.2967/jnumed.110.078592. Epub 2010 Sep 16.

41.

Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.

Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG.

Cancer Res. 2010 Nov 1;70(21):8299-308. doi: 10.1158/0008-5472.CAN-10-0851. Epub 2010 Sep 13.

42.

Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.

Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J.

J Nucl Med. 2010 Aug;51(8):1174-81. doi: 10.2967/jnumed.109.074229. Epub 2010 Jul 21.

43.

Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.

Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH.

J Nucl Med. 2010 Aug;51(8):1285-92. doi: 10.2967/jnumed.109.073585. Epub 2010 Jul 21.

44.

A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.

Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, Liu M, Zhang N, Wang S, Angenieux B, Panosyan E, Samuels ER, Park J, Williams D, Konkankit V, Nathanson D, van Dam RM, Phelps ME, Wu H, Liau LM, Mischel PS, Lazareff JA, Kornblum HI, Yong WH, Graeber TG, Tseng HR.

Cancer Res. 2010 Aug 1;70(15):6128-38. doi: 10.1158/0008-5472.CAN-10-0076. Epub 2010 Jul 14.

45.

Novel PET probes specific for deoxycytidine kinase.

Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG.

J Nucl Med. 2010 Jul;51(7):1092-8. doi: 10.2967/jnumed.109.073361. Epub 2010 Jun 16. Erratum in: J Nucl Med. 2015 Feb;56(2):329.

46.

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.

Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC.

Sarcoma. 2010;2010:143540. doi: 10.1155/2010/143540. Epub 2010 Apr 18.

47.

Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.

Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC.

J Nucl Med. 2010 May;51(5):720-7. doi: 10.2967/jnumed.109.068361. Epub 2010 Apr 15.

48.

Maximal entropy inference of oncogenicity from phosphorylation signaling.

Graeber TG, Heath JR, Skaggs BJ, Phelps ME, Remacle F, Levine RD.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6112-7. doi: 10.1073/pnas.1001149107. Epub 2010 Mar 11.

49.

Requirement for deoxycytidine kinase in T and B lymphocyte development.

Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5551-6. doi: 10.1073/pnas.0913900107. Epub 2009 Dec 31.

50.

Epithelial uptake of [18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice.

Brewer S, Nair-Gill E, Wei B, Chen L, Li X, Riedinger M, Campbell DO, Wiltzius S, Satyamurthy N, Phelps ME, Radu C, Witte ON, Braun J.

Gastroenterology. 2010 Apr;138(4):1266-75. doi: 10.1053/j.gastro.2010.01.003. Epub 2010 Jan 18.

Supplemental Content

Loading ...
Support Center